We are forgetting about health tech, and celebrating Chicago-oo! Just kidding, today on Health in 2 Point 00, Jess asks me about Truepill getting a 75M Series C after just closing their B, Sana Benefits getting $20.8M, and Decent getting $10M, both of which are in the space of health benefits & insurance for small business have raised funding, MDLive closing a $50M round for their Virtual Primary Care (but weren’t they going public?), Owl Insights getting $15M from Ascension and Blue Ventures, and Boehringer Ingelheim & Click Therapeutics working on a $500M deal together on a DTx platform for Schizophrenia patients. –Matthew Holt
The Digital Therapeutics Startup Following Pharma’s Formulary Model | David Klein, Click Therapeutics
By JESSICA DaMASSA, WTF HEALTH
Click Therapeutics is a digital therapeutics company that develops and commercializes “software as medical treatments” — basically building digital formularies of prescribable software tools the same way a traditional pharma company would create a formulary of prescription drugs. CEO David Benshoof Klein stops by to talk about Click’s array of solutions and the support they’ve received from those traditional pharma companies, including investment from Sanofi-Genzyme BioVentures (which led their last funding round of $27.4M in October 2018) and a new partnership with Otsuka America, Inc. to fully fund development of an app to combat Major Depressive Disorder.
Filmed at Frontiers Health in Berlin, Germany, November 2019.
